We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Oxytocin and Emotion Recognition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01216605
Recruitment Status : Completed
First Posted : October 7, 2010
Last Update Posted : October 7, 2010
Information provided by:
University Hospital Freiburg

Brief Summary:
The present study was designed to investigate the effects of a single dose of synthetic oxytocin on facial emotion recognition in healthy adult man. Pictures of emotional faces are presented very briefly for a few milliseconds in a backward-masking paradigm in order to vary the level of awareness. In a randomized placebo-controlled between-subject design, recognition performance is compared between a drug (24 IU oxytocin) and a placebo condition. We hypothesize that oxytocin enhances emotion recognition even for facial stimuli processed with limited awareness.

Condition or disease Intervention/treatment Phase
Health Drug: Syntocinon 24 IU Drug: Placebo Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Study Start Date : November 2009
Primary Completion Date : January 2010
Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Oxytocin
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Oxytocin Drug: Syntocinon 24 IU
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Performance on a facial emotion recognition task [ Time Frame: 45 min. following drug administration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males
  • 18 to 40 years of age

Exclusion Criteria:

  • Any psychiatric diagnosis life-time
  • Somatic disease
  • IQ < 85
  • Smoker
  • Psychoactive medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01216605

Department of PSychiatry University of Rostock
Rostock, D, Germany, 18055
Sponsors and Collaborators
University Hospital Freiburg
Principal Investigator: Gregor Domes, PhD University of Freiburg

ClinicalTrials.gov Identifier: NCT01216605     History of Changes
Other Study ID Numbers: X01A-DO1312/1-1
DO1312/1-1 ( Other Grant/Funding Number: German Research Foundation (DFG) )
First Posted: October 7, 2010    Key Record Dates
Last Update Posted: October 7, 2010
Last Verified: October 2010

Additional relevant MeSH terms:
Reproductive Control Agents
Physiological Effects of Drugs